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Abstract
Background: Insulin-like growth factor-I receptor (IGFIR) has been shown to regulate the tumor development. The 
objective of the current study is to determine the association of IGFIR with lymph node metastasis and to explore the 
related mechanism in human colorectal cancer in clinic.
Methods: In a random series of 98 colorectal cancer patients, the expressions of IGFIR, vascular endothelial growth 
factor (VEGF) and VEGF-C were investigated by immunohistochemistry, and the association of these expressions with 
lymph node metastasis was statistically analyzed. The expressions of VEGF and VEGF-C in colorectal cancer cells 
stimulated with IGF-I were also examined by real-time quantitative reverse transcription-polymerase chain reaction 
and enzyme-linked immunosorbent assay.
Results: Higher rates of IGFIR (46%), VEGF (53%), and VEGF-C (46%) expression were found in colorectal cancer tissues 
than in normal and colorectal adenoma tissues. These expressions were significantly associated with clinicopathologic 
factors and lymph node status. We also found the concomitant high expressions of IGFIR/VEGF (P < 0.001) and IGFIR/
VEGF-C (P = 0.001) had a stronger correlation with lymph node metastasis than did each alone or both low expressions. 
In addition, IGF-I could effectively induce the VEGF and VEGF-C mRNA expression and protein secretion in colorectal 
cancer cells expressing IGFIR molecules. Moreover, Patients who had strong staining for IGFIR, VEGF and VEGF-C 
showed significantly less favorable survival rates compared with patients who had low staining for these molecules (P 
< 0.001). The survival rates of patients who were both high expression of IGFIR/VEGF and IGFIR/VEGF-C also were 
significantly lower compared with patients who were negative or one of high expression of these molecules (P < 
0.001).
Conclusions: Together the findings indicated for the first time that simultaneous examination of the expressions of 
IGFIR, VEGF and VEGF-C will benefit the diagnosis of lymph node metastasis in order to assay the prognosis and 
determine the treatment strategy in patients with colorectal cancer undergoing surgery.
Background
Colorectal cancer is a major global health problem and
the fourth most common cause of cancer death world-
wide [1]. Distal metastasis that results from lymph node
metastasis is one of the main causes of colorectal cancer
death and is an unsolved difficult issue in clinical treat-
ment. Accumulating evidence indicates that a variety of
tumor systems including colorectal cancers express high
levels of insulin-like growth factor-I receptor (IGFIR)
[2,3], which initiates intracellular signaling cascades that
enhance cell cycle progression and inhibit apoptosis [4],
finally led to prosperity of cancer cells and increased
tumor invasion [5,6]. Moreover, small-molecule inhibi-
tors and antisense oligonucleotides to IGFIR could effi-
ciently suppress the growth and proliferation of human
cancer cells in vitro [7,8] and decrease lymph node
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metastasis in a mouse tumor model [9]. However, how
IGFIR regulates tumor growth and lymph node metasta-
sis in human colorectal carcinomas in clinic is still not
well understood.
Angiogenesis has been known to play an important role
in the development of tumor growth and lymph node
metastasis. Vascular endothelial growth factor (VEGF)
family is the most widely investigated and most specific
regulator of angiogenesis, which consist of six members
including VEGF-A, -B, -C, -D, -E and placenta growth
factor. They potently increase vascular permeability and
promote the formation of new blood vessels in tumors
and thus are regarded as the main growth stimulatory
factors in the tumor-related angiogenesis [10]. The prog-
nostic value of high expression of VEGF (or VEGF-A) for
lymph node metastasis has been demonstrated in various
types of human cancer [10-12]. Most recent studies dem-
onstrated that stimulation of IGFIR in colorectal cancer
cells induced the expression of VEGF, which can further
promote the progression of cancer by regulating the
development of new blood vessels [13,14]. In comparison,
blocking the IGFIR led to significant down-regulation of
VEGF and inhibition of tumor growth and lymph node
metastasis [7-9]. These observations suggest that IGFIR
can promote the tumor growth and lymph node metasta-
sis through the induction of VEGF.
The regional lymph nodes draining primary tumors are
generally the first, and by far the most common, site of
metastasis for some of the major human malignancies,
and tumor cell dissemination to the regional lymph node
was generally believed to be a passive process. Recent evi-
dence suggests that tumor-derived VEGF-C and VEGF-D
can stimulate de novo formation of intratumoral lym-
phatic capillaries (lymphangiogenesis), which raised the
possibility that cells within primary tumors can contrib-
ute actively to lymphatic dissemination through the
induction of lymphangiogenesis [15]. When overex-
pressed in breast cancer MCF-7 cells, VEGF-C promoted
tumor lymphangiogenesis and tumor metastasis [16].
Notably , IGF-I has recently been demonstrated to be a
positive regulator of VEGF-C expression through IGFIR
signaling and implicated in the control of lymphatic
metastasis [17].
Based on these observations, we wished to clarify the
mechanism by which IGFIR regulate tumor growth and
lymph node metastasis in human carcinomas. For this
purpose, we investigate the expressions of IGFIR, VEGF
and VEGF-C and the association of these expressions
with lymph node metastasis in human colorectal cancer
and relative cancer cell line. Our results show that the
concomitant high expressions of IGFIR and VEGF or
VEGF-C is positively correlated with lymph node metas-
tasis in human colorectal cancer in a significant manner,
which could provide valuable information in predicting
and diagnosing lymph node metastasis.
Methods
Patients and specimens
Sections of paraffin-embedded tissue samples were pro-
vided by the Department of Pathology, Pudong New Area
People's Hospital, Shanghai, China. They were obtained
from patients with colorectal cancer and included 98 col-
orectal cancer tissue samples and 26 adjacent normal tis-
sue samples. There were also 38 colorectal ademona
tissues. Informed consent for sample collection and anal-
ysis of their tissue for research purposes in this study was
obtained from the subjects. We retrospectively reviewed
all patients who underwent curative-intent surgery and
were randomly selected at the Department of Surgery
from 2002 to 2005. Ethical approval was obtained to per-
form this research study from the Ethical Committee of
Pudong New Area People's Hospital in Shanghai, China.
Forty-eight of the 98 colorectal cancer patients had histo-
logically confirmed lymph node metastasis. Tumors were
staged according to the American Joint Committee on
Cancer pathologic tumor-node-metastasis (TNM) classi-
fication. None of the patients had received pre-operative
chemotherapy or radiotherapy therapy.
Immunohistochemistry
Sections were subjected to routine deparaffinization and
rehydration. Antigen retrieval was achieved by micro-
waving sections in 0.01 mol/L citrate buffer for 10 min
and then cooling for 30 min. The endogenous peroxidase
activity was inhibited by incubation with 3% hydrogen
peroxide in methanol for 20 min and nonspecific binding
was blocked by incubation with 5% bovine serum albu-
min in phosphate-buffered saline (PBS) at room tempera-
ture. After three PBS washes, the specimens were reacted
overnight at 4°C with rabbit anti-human IGFIR poly-
clonal antibody (Abgent, San Diego, CA, USA), mouse
anti-human VEGF monoclonal antibody (Lab Vision
Corp., Fremont, CA, USA) or rabbit anti-human VEGF-C
polyclonal antibody (Zymed Laboratories, Inc., South San
Francisco, CA, USA). After incubation at 37°C with EnVi-
sion™ (DAKO, Hamburg, Germany) for 30 min, signal
was developed with 3,3'-diaminobenzidine tetrahydro-
chloride in Tris-HCl buffer (pH 7.6) containing 0.3%
hydrogen peroxide. The sections were then counter-
stained with hematoxylin and mounted. Negative con-
trols were performed by replacing the specific primary
antibody with normal mouse serum or PBS.
Interpretation and evaluation of immunohistochemical 
results
Immunostaining was independently examined by two
clinical pathologists who were unaware of the patientZhang et al. BMC Cancer 2010, 10:184
http://www.biomedcentral.com/1471-2407/10/184
Page 3 of 11
outcome. For each sample, five high-power fields (200×)
were randomly selected. The percentage of positive
tumor cells and staining intensity were assessed. The
extent of the staining was categorized into five semiquan-
titative classes based on the percentages of positive tumor
cells: 0 (≤ 5% positive cells), 1 (6%-25% positive cells), 2
(26%-50% positive cells), 3 (51%-75% positive cells) and 4
(>75% positive cells). The intensity of cytoplasmic and
membrane staining was also determined semiquantita-
tively on a scale of 0-3 as follows: 0 (negative), 1 (weakly
positive), 2 (moderately positive) and 3 (strongly posi-
tive). A consensus score was assigned for each section
after discussion and careful review of all slides by the two
pathologists.
Multiplication of the intensity and the percentage
scores gave rise to the final staining score: 0 (negative), +
(1-4), ++ (5-8), and +++ (9-12). For statistical analysis,
tumors that scored 0 or +, which showed weak or moder-
ate/strong immunoreactivity, were lumped into a low
expression group and were compared to tumors with
scores of ++ or +++ as the high expression group.
Induction of VEGF and VEGF-C expression by IGF-I
COLO 205 cells, a colorectal cancer cells line, were plated
in 96-well plates and cultured overnight at 37°C in Dul-
becco's modified Eagle's medium (1 × 106/ml) supple-
mented with 10% fetal bovine serum, penicillin (100 U/
ml) and streptomycin (100 mg/ml). The medium was
aspirated, and fresh, serum-free medium containing vari-
ous concentrations of IGF-I (0, 20, 50, 100, 250 ng/ml)
was then added into each well. After another 48-h culture
at 37°C, the cells and supernatants were collected. Total
RNA was extracted from the cells by Trizol reagents, and
VEGF and VEGF-C mRNA levels were analyzed by real-
time quantitative reverse transcription-polymerase chain
reaction (qRT-PCR). VEGF and VEGF-C secretion in the
culture supernatant was analyzed by enzyme-linked
immunosorbent assay (ELISA).
Statistical analysis
Chi-squared test and two-sided Fisher's exact test were
applied to determine the strength of association between
the categorical variables. The correlations between
expression of IGFIR, VEGF and VEGF-C and several clin-
icopathologic parameters were assessed with the χ2 test or
the Spearman rank test. Survival rates were calculated
using the Kaplan-Meier method, and significant differ-
ences in survival were determined by log-rank test. All
statistical analyses were performed using a statistical soft-
ware package (SPSS, Inc., Version 10.0, Chicago, IL,
USA). All tests were two-sided, and P values < 0.05 were
considered statistical significance.
Results
IGFIR, VEGF and VEGF-C expression in different colorectal 
tissues
IGFIR exhibited cytoplasmic and membrane staining.
Two out of 26 normal tissues adjacent to the tumor cells
showed weak IGFIR staining, and the rest were negative
for IGFIR. Among the 38 colorectal adenoma tissues, 6
were negative for IGFIR, 3 exhibited strong positive stain-
ing and the rest had positive but weak IGFIR staining.
The frequency of positive IGFIR staining in colorectal
adenoma was higher than that in normal tissues. In strik-
ing contrast, all 98 colorectal cancer cases showed posi-
tive IGFIR staining with 45 cases (46%) being high
expressors (Figure 1). As shown in Table 1, there are
highly significant differences in terms of the number of
cases with high IGFIR expression between the colorectal
cancer and the normal group (P < 0.001) or between the
cancer and the adenoma group (P < 0.001). VEGF and
VEGF-C immunoreactivity, localized mainly to the cyto-
plasm, was weak in normal and adenoma samples, but
their staining was much stronger in cancer tissues (53%
for VEGF and 46% for VEGF-C; Figure 1).
Association of IGFIR, VEGF and VEGF-C expression with 
clinicopathologic features
The clinical, epidemiologic, and histopathologic charac-
teristics of patients with colorectal cancers, and the asso-
ciation of high expression of IGFIR, VEGF, and VEGF-C
with clinicopathologic parameters were shown in Table 2.
There was a statistically significant correlation between
TNM stage and the level of IGFIR (P < 0.001), VEGF (P =
0.001) or VEGF-C (P = 0.006). The increased expressions
were significantly associated with advanced histological
Table 1: Expression of IGFIR in Different Colorectal Tissues.
Case No. IGFIR expression P value
Low or negative High
Colorectal tumor 98 53 (54%) 45 (46%)a < 0.001 (a vs. b)
Colorectal adenoma 38 35 (92%) 3 (8%)b 0.265 (b vs. c)
Normal colorectal 
tissues
26 26 (100%) 0 (0%)c < 0.001 (a vs. c)Zhang et al. BMC Cancer 2010, 10:184
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grade (P < 0.001 for IGFIR, P = 0.007 for VEGF and P <
0.001 for VEGF-C). There were no statistically significant
associations in the expression of these molecules with
regard to patient age, gender, tumor position or the loca-
tion of tumor infiltration.
Association of high expression of IGFIR with lymph node 
metastasis
Vascular invasion directly influences the status of lymph
node metastasis. Out of 49 cancer samples positive for
vascular invasion, there were 30 cases (61%) showing
high expression of IGFIR, whereas only 15 cases (31%) for
49 samples of negative vascular invasion (P  = 0.002).
There was also a significant correlation between IGFIR
expression levels and lymph node metastasis. Thirty-one
cases (65%) out of 48 samples positive for lymph node
metastasis showed high expression of IGFIR in both col-
orectal cancer tissues and related metastatic lymph
nodes, whereas only 14 cases (28%) for 50 samples of neg-
ative lymph node metastasis (P < 0.001; Table 2). These
data suggested that IGFIR may play an important role in
the promotion of lymph node metastasis in human col-
orectal cancer.
Association of single or combined high expression of IGFIR 
and VEGF or VEGF-C with lymph node metastasis
We then analyzed the combined effects of IGFIR and
VEGF or VEGF-C in human colorectal cancer . Statistic
analysis showed a significant association of increased
e x p r e s s i o n  o f  I G F I R ,  V E G F ,  a n d  V E G F - C  w i t h  l y m p h
node metastasis in patients suffering from colorectal can-
cer. The incidence of lymph node metastasis tended to be
higher in cases with high rather than low expression of
IGFIR, VEGF and VEGF-C, respectively (P < 0.01; Table
2). We further compared the correlation of colorectal
cancer lymph node metastasis with combined high
expression of both IGFIR and VEGF or of both IGFIR and
VEGF-C. The incidence of lymph node metastasis was
significantly higher in patients with tumors highly
expressing both IGFIR and VEGF (75%) than those of
patients with tumor highly expressing only one or none of
the molecules (34%). Similarly, higher rate of lymph node
metastasis was observed in patients with tumors highly
expressing both IGFIR and VEGF-C (70%) than those of
patients with tumors highly expressing only one or none
o f  t h e  m o l e c u l e s  ( 3 6 % ) .  N o t a b l y ,  w h e n  c o m p a r e d  w i t h
both low or one of high expression of these markers, the
concomitant high expressions of IGFIR and VEGF or
IGFIR and VEGF-C was statistically significantly associ-
ated with lymph node metastasis in patients with colorec-
tal cancer (Table 3; P < 0.001 for IGFIR/VEGF and P =
0.001 for IGFIR/VEGF-C).
Interrelationship between IGFIR and VEGF or VEGF-C 
expression
We further examined whether the expression of IGFIR
was significant correlated with the expression of VEGF or
VEGF-C in human colorectal tumor. Among the 45 col-
orectal tumor samples with high expression of IGFIR, 36
cases showed high expression of VEGF and also 36 cases
for VEGF-C. In addition, statistical analysis indicated that
high expression of IGFIR was positively correlated with
the high expression of VEGF (Table 4; r = 0.497, P  <
0.001) and VEGF-C (Table 4; r = 0.516, P < 0.001).
IGF-I induced VEGF and VEGF-C expression in colorectal 
cancer cells
To investigated the possible the relationship of IGFIR
expression and VEGF or VEGF-C in human colorectal
carcinoma, a colorectal cancer cell line COLO 205, which
expressed IGFIR molecules, were used and stimulated
with various dose of IGF-I. Expression of VEGF and
VEGF-C mRNA was then determined by real-time qRT-
PCR, and secreted VEGF and VEGF-C were analyzed by
ELISA. As shown in Figure 2, there was a dose dependent
increase of VEGF and VEGF-C mRNA and protein upon
the stimulation of IGF-I, suggesting that the expression of
Figure 1 Representative examples of immunohistochemical 
staining of IGFIR, VEGF, and VEGF-C in colorectal cancer. Positive 
staining is shown in dark brown. Colorectal adenoma tissues were 
stained with IGFIR (A), VEGF (C), VEGF-C (E) as controls, and colorectal 
cancer tissues showed strong staining of IGFIR (B), VEGF (D), and VEGF-





























































































Table 2: Correlation of IGFIR, VEGF and VEGF-C Expression with Clinicopathologic Features in Colorectal Tumor.
Clinicopathologic 
parameters
Case No. IGFIR expression P value VEGF expression P value VEGF-C expression P 
value
L o wH i g h L o wH i g h L o wH i g h
Total cases 98 53 (54%) 45 (46%) 46 (47%) 52 (53%) 53 (54%) 45 (46%)
Age
≤50 25 14 (56%) 11 (44%) 0.824 11 (44) 14 (56%) 0.733 14 (56%) 11 (44%) 0.351
>50 73 39 (53%) 34 (47%) 35 (45%) 38 (55%) 33 (45%) 40 (55%)
Gender
Male 55 29 (53%) 26 (47%) 0.761 24 (44%) 31 (56%) 0.459 28 (51%) 27 (49%) 0.509
Female 43 24 (56%) 19 (44%) 22 (51%) 21 (49%) 19 (44%) 24 (56%)
Tumor position
Colon 44 20 (45%) 24 (55%) 0.122 19 (43%) 25 (57%) 0.501 23 (52%) 21 (48%) 0.440
Rectum 54 33 (61%) 21 (39%) 27 (50%) 27 (50%) 24 (44%) 30 (56%)
Infiltration location
Submucosa 30 19 (63%) 11 (37%) 0.109 17 (57%) 13 (43%) 0.180 15 (50%) 15 (50%) 0.052
Muscularis 
propria
6 1 (17%) 5 (83%) 1 (17%) 5 (83%) 0 (0%) 6 (100%)
Outer layer 62 33 (53%) 29 (47%) 28 (45%) 34 (55%) 32 (52%) 30 (48%)
TNM stage
I 24 18 (75%) 6 (25%) < 0.001 16 (67%) 8 (33%) 0.001 13 (54%) 11 (46%) 0.006
II 32 23 (72%) 9 (28%) 20 (63%) 12 (37%) 22 (69%) 10 (31%)
III 36 10 (28%) 26 (72%) 8 (22%) 28 (78%) 10 (28%) 26 (72%)
IV 6 2 (33%) 4 (67%) 2 (33%) 4 (67%) 2 (33%) 4 (67%)
Histologic 
differentiation
Poor 30 6 (20%) 24 (80%) < 0.001 7 (23%) 23 (77%) 0.007 5 (17%) 25 (63%) < 0.001
Moderate 44 30 (68%) 14 (32%) 24 (55%) 20 (45%) 24 (55%) 20 (45%)
Good 24 17 (71%) 7 (29%) 15 (63%) 9 (37%) 18 (75%) 6 (25%)
Vascular invasion
Negative 49 34 (69%) 15 (31%) 0.002 34 (69%) 15 (31%) < 0.001 32 (65%) 17 (35%) 0.001
Positive 49 19 (39%) 30 (61%) 12 (24%) 37 (76%) 15 (31%) 34 (69%)
Lymph node 
metastasis
Negative 50 36 (72%) 14 (28%) < 0.001 30 (60%) 20 (40%) 0.008 32 (64%) 18 (36%) 0.001
Positive 48 17 (35%) 31 (65%) 16 (33%) 32 (67%) 15 (31%) 33 (69%)
Abbreviations: IGFIR, insulin-like growth factor-I receptor; VEGF, vascular endothelial growth factor; TNM, tumor-node-metastasis.Zhang et al. BMC Cancer 2010, 10:184
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VEGF and VEGF-C could be induced in human colorec-
tal cancer through IGFIR signal.
Prognostic impact of IGFIR, VEGF and VEGF-C expression
The prognostic impacts of IGFIR, VEGF and VEGF-C
expression were analyzed by using Kaplan-Meier survival
curves. Patients who had strong IGFIR, VEGF and VEGF-
C staining showed a significantly lower survival rate com-
pared with patients who had low staining (Figure 3, P <
0.001). Survival rates also were evaluated according to
combinations of IGFIR/VEGF and IGFIR/VEGF-C co-
expression. Patients who were both high expression of
IGFIR/VEGF and IGFIR/VEGF-C had unfavorable prog-
noses, and patients who were negative or one of high
expression of these molecules had more favorable prog-
noses (Figure 4, P < 0.001).
Discussion
In this study, we found that simultaneously high expres-
sion of IGFIR and VEGF or VEGF-C were valuable pre-
dictive biomarker of lymph node metastasis in human
colorectal cancer. Furthermore, statistical analysis and in
vitro results indicated that elevated IGFIR expression was
responsible for the upregulation of VEGF and VEGF-C,
which then promote the lymph node metastasis in human
colorectal cancer.
Malignant tumor metastasis is the result of a series of
complex processes that depend on multiple and interac-
tive factors. IGFIR signaling has recently been inferred to
play a role in tumor growth and the invasive and meta-
static ability in various carcinomas in vitro and in animal
models [18]. VEGF, which stimulates the migration and
proliferation of endothelial cells, has been well recog-
nized as a crucial regulatory factor in tumor angiogene-
sis. A number of studies have demonstrated that VEGF
can induce tumor growth and promote lymphatic metas-
tasis [19,20]. Lymphangiogenic factors, such as VEGF-C
and VEGF-D, have been show to stimulate tumor lymp-
hangiogenesis and metastasis to regional lymph nodes by
interacting with their receptor VEGF receptor 3 (VEGFR-
3). High levels of VEGF-C and VEGF-D can promote
tumor growth and lymph node metastasis in human col-
orectal cancer. Moreover, strong expression of VEGF-C
and VEGF-D was significantly linked to a trend for
decreased survival in colorectal cancer patients [21-25].
Our results in pathology indicated that high expression of
each of these three markers was much more frequent in
human colorectal cancer tissues than in normal tissues or
non-tumor lesions. While the expression of IGFIR, VEGF
and VEGF-C correlated with tumor TNM stage, the
increased expression of IGFIR, VEGF, and VEGF-C also
correlated with histological grade. Our observations sug-
Table 3: Correlation of Combined High Expression of IGFIR and VEGF or VEGF-C with Lymph Node Metastasis.
Lymph node metastasis P value
Negative Positive
IGFIR/VEGF
Both low or one of high 
expression
41 21 < 0.001
Both high expression 9 27
IGFIR/VEGF-C
Both low or one of high 
expression
39 22 0.001
Both high expression 11 26
Table 4: Correlation Analysis between High Expression of IGFIR and VEGF or VEGF-C in Colorectal Tumor.
IGFIR VEGF VEGF-C
Low High Low High
L o w 3 71 63 81 5
High 9 36 9 36
r = 0.497 r = 0.516
P < 0.001 P < 0.001
Correlation coefficients (r) were calculated by Spearman rank correlation analysis.Zhang et al. BMC Cancer 2010, 10:184
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gest that these molecules play important roles in mediat-
ing the tumor progression of malignancy. Furthermore,
we found that the expression of IGFIR, VEGF, and VEGF-
C significantly correlated with lymph node status. Thus,
investigating the expression and relationship of these
markers may elucidate the mechanism by which regulates
lymph node metastasis in human colorectal cancer.
It was implied that IGFIR play a role in tumor growth
and lymph node metastasis in various cancers cells [18].
We found that the cases of high expression of IGFIR were
more in the patients with positive lymph node metastasis
than that with negative lymph node metastasis. More-
over, there is a statistically significant correlation of high
expression of IGFIR in colorectal cancer tissue with
lymph nodes metastasis, suggesting that patients suffer-
ing from colorectal cancer with high expression of IGFIR
have stronger lymph node metastatic possibility.
Recently, some of in vitro experiments indicated that
IGFIR can increase VEGF expression and stimulate
tumor angiogenesis in pancreatic carcinoma cells [26,27].
Moreover, inhibiting IGFIR signaling can not only down-
regulate the expression of VEGF, but also decrease the
number of tumor-related blood vessels, increase cancer
cell apoptosis and lose lymph node metastatic ability to
distal organs [28]. It is likely that tumor progression and
metastasis could be promoted by IGFIR via the induction
of angiogenesis. However, although the evidences for
IGFIR-VEGF interaction have been put forward in the
results in vitro, there is still lack of evidence currently
available on the biological relationship between these two
molecules in human colorectal cancer in clinic. In our
study, we showed a significant correlation between the
high expressions of IGFIR and VEGF in human colorectal
cancer samples. In addition, the concomitant high
expressions of both molecules were more predictive of
lymph node involvement as compared with that of a sin-
gle marker high expression or both low expressions. Fur-
thermore, IGF-I could effectively stimulate VEGF mRNA
expression and protein secretion in human colorectal
cancer cells expressing IGFIR molecules, which implied
Figure 2 Induction of VEGF and VEGF-C by IGF-I in colorectal cancer cell. COLO 205 cells were incubated with various concentrations of IGF-I for 
48 h at 37°C. The expression of VEGF (A) and VEGF-C (B) was analyzed by qRT-PCR in COLO 205 cells, and normalized to endogenously expressed β-
actin in the same sample. VEGF (C) and VEGF-C (D) protein secretion in the cell culture supernatant was quantified using ELISA. Results are expressed 
as the mean ± SD of triplicate cultures and are represented of 3 independent experiments.Zhang et al. BMC Cancer 2010, 10:184
http://www.biomedcentral.com/1471-2407/10/184
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VEGF receptor VEGFR could also be up-regulated to
promote the induction of angiogenesis, Therefore, VEGF
and its receptor VEGFR may be a downstream molecule
that is regulated by IGFIR signaling, and they may have
synergistic effects in colorectal cancer growth and lymph
node metastasis.
Metastatic tumor spread through the blood or lym-
phatic vessels occurs in most forms of human cancer,
w i t h  r e g i o n a l  l y m p h  n o d e  m e t a s t a s i s  o f t e n  b e i n g  t h e
most important prognostic factor for carcinoma patients
[29]. It was reported that IGF-I can act as a direct lymp-
hangiogenic factor through the activation of intracellular
s i g n a l  c o m p o n e n t s,  s u c h  a s  A k t,  S r c ,  a n d  e x t r a c e l l u l a r
signal-regulated kinase in tumor lymphatic endothelial
cells [30]. Furthermore, M-27 cells, a Lewis lung carci-
noma subline, transfected with human IGFIR cDNA
expressed high levels of VEGF-C mRNA and protein in
response to IGF-I [17]. These results implied that IGFIR
may stimulate the expression of VEGF-C, and indirectly
modulate the potential of tumor lymph node metastasis.
By immunohistochemical staining, we found that in
human colorectal cancer samples that expressed high lev-
els of both IGFIR and VEGF-C, 70% were positive for
lymph node metastasis, and the co-expression of IGFIR
and VEGF-C in the tumor correlated with an increased
incidence of lymph node metastasis. In addition, our data
showed that IGFIR high expression was positively corre-
lated with VEGF-C high expression, and the expression of
VEGF-C in mRNA and protein level also could be effec-
tively induced by IGF-I in human colorectal cancer cells
expressing IGFIR molecules, implying VEGF-C receptor
VEGFR-3 could also be stimulated to promote lymp-
hangiogenesis. Thus, IGFIR and VEGF-C may also play a
synergistic role in human colorectal cancer metastasis,
Figure 3 Kaplan-Meier analysis of overall survival for IGFIR, VEGF and VEGF-C expression. Survival curves for patients with colorectal cancer 
were stratified by the expression of IGFIR (A), VEGF (B) and VEGF-C using the Kaplan-Meier method. Patients who had strong staining for IGFIR, VEGF 
and VEGF-C showed significantly less favorable survival rates compared with patients who had low staining for these molecules (P < 0.001).Zhang et al. BMC Cancer 2010, 10:184
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and this process may partly contribute to the upregula-
tion of VEGF-C by IGFIR.
PI3K has been identified as a major transducer of the
IGFIR signal in various cellular systems. Among others,
its activity was shown to be critical for cell survival, a
function mediated through Akt and Bax activation, and it
was implicated in mitogenesis, protein synthesis, and dif-
ferentiation. The degree to which different cells use com-
mon pathways to convey the IGFIR signals may be cell
context dependent [17]. Thus, IGFIR signaling elevated
VEGF and VEGF-C expression could be mediated by
PI3K pathway, which may be possible mechanisms
underlying induction of VEGF and VEGF-C by IGF-I in
human colorectal cancer cell lines or tumor samples.
Predictive prognostic markers in colorectal cancer were
studied, and a few statistically significant associations
between the studied markers and longterm prognosis
were found. In the current study, we found a clear and
significant correlation between high IGFIR, VEGF and
VEGF-C expression and lymph node metastasis in
human colorectal cancer. In addition, high expression of
these molecules in colorectal cancer patients showed sig-
nificantly less favorable survival rates. The combination
analysis of IGFIR/VEGF and IGFIR/VEGF-C co-expres-
sion demonstrated a negative impact on prognosis.
Therefore, these findings may enable more an accurate
assessment of the predictive prognosis of patients with
colorectal cancer.
Conclusion
The present study demonstrates that IGFIR, VEGF, and
VEGF-C are highly expressed in human colorectal cancer
and that their expression is interrelated. In addition, the
concomitant high expressions of IGFIR/VEGF or IGFIR/
VEGF-C were significantly associated with lymph node
metastasis and negatively impacted on survival rate in
human colorectal cancer. Moreover, VEGF and VEGF-C
could be effectively induced by IGF-I in human colorectal
cancer cells expressing IGFIR molecules. These observa-
tions suggest that lymph node metastasis in human col-
orectal cancer could be promoted by elevated IGFIR
expression via upregulation of VEGF and VEGF-C. Over-
all, combined analysis of IGFIR and VEGF or VEGF-C
will prove to be invaluable for predicting lymph node
metastasis in human colorectal cancer. Inhibition of
IGFIR/IGF-I based on this mechanism may develop an
effective treatment for human colorectal cancer. This
study would provide a novel insight into diagnosis of
lymph node metastasis and therapeutic strategy of tumor
in human colorectal cancer.
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